Herantis Pharma publishes newsletter for March-April
Herantis Pharma Plc
Press release 6 May 2019 at 9:00 am
Herantis Pharma plc (“Herantis”) has published its newsletter for March-April. The newsletter is also attached to this press release.
Herantis’ newsletter is published every other month on the company’s web site. It is also available by email subscription.
Further information:
Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.
Distribution:
Main media
www.herantis.com
Attachment
